TABLE 3-continued

Benzonapthyridine SMIPs 28, 29, and 30 Protected Mice in Ebola Virus Challenge Model.

Compound	Dose (μg)	% mice alive on indicated day (challenged with EboZ on day 0)													
		0	1	2	3	4	5	6	7	8	9	10	11	12	13
Pam3CSK4	10	100	100	100	100	100	30	0	0	0	0	0	0	0	0
	100	100	100	100	100	100	30	10	0	0	0	0	0	0	0
Ebola VLP	50	100	100	100	100	100	100	100	100	100	100	100	100	100	100
poly(IC)	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100
PBS	none	100	100	100	100	100	100	100	90	40	20	20	20	20	10

[0998] Additional doses, as indicated in Tables 4 and 5, of benzonapthyridine SMIP 28 and SMIP 29 were tested. The same experimental design was used as in the experiments conducted to generate the date in Table 3 with one exception. Instead of PBS as a negative control, peanut oil was used, and all SMIPs were dissolved in peanut oil. For each dose of compound or dose of control compound tested, ten mice were treated. FIG. **2** presents some of the data shown in Table 4. Consistent with the previous study (Study 3), SMIPs 28 and 29 protected mice that were infected with EBOV. Protection measured on day 8 was observed at doses as low as 1 μg of SMIP 28 or SMIP 29. As observed with the experiments for which data is presented in Table 3, R-848, in the experiments for which data is presented in Tables 4 and 5, did not protect mice infected with EBOV. It should be noted that the failure of the Ebola VLP to protect was considered highly unusual and not reproducible, and probably the result of some unexplained technical failure.

[0999] Tables 4 and 5: SIMPs 28 and 29 protected mice in Ebola Virus Challenge model.

TABLE 4

Compound	Dose (μg)	% mice alive on indicated day (challenged with EboZ on day 0)														
		0	1	2	3	4	5	6	7	8	9	10	11	12	13	14
Peanut oil	none	100	100	100	100	100	90	90	20	10	nr	nr	nr	nr	nr	nr
R-848	1	100	100	100	100	100	100	100	100	40	nr	nr	nr	nr	nr	nr
	10	100	100	100	100	100	100	100	80	10	nr	nr	nr	nr	nr	nr
	100	100	100	100	100	100	100	100	50	10	nr	nr	nr	nr	nr	nr
SMIP 28	1	100	100	100	100	100	100	100	100	100	100	100	100	nr	nr	nr
	3	100	100	100	100	100	100	100	100	80	nr	nr	50	nr	nr	nr
	10	100	100	100	100	100	100	100	100	100	nr	nr	90	nr	nr	nr
	30	100	100	100	100	100	100	100	100	100	100	100	100	nr	nr	nr
	100	100	100	90	90	90	90	90	80	30	nr	nr	0	0	0	0
SMIP 29	1	100	100	100	100	100	100	100	100	100	nr	nr	90	nr	nr	nr
	3	100	100	100	100	100	100	100	90	80	nr	nr	70	nr	nr	nr
	10	100	100	100	100	100	100	90	90	90	nr	nr	50	nr	nr	nr
	30	100	100	100	100	100	100	100	100	80	nr	nr	0	nr	nr	nr
	100	100	100	100	100	100	100	100	40	40	nr	nr	20	nr	nr	nr
Ebola VLP	50	100	100	100	100	100	100	100	50	0	0	0	0	0	0	0

nr: not reported

EboZ: mouse-adapted strain derived from the Zaire strain of Ebola virus

TABLE 5

Compound	Dose (μg)	% mice alive on indicated day (challenged with EboZ on day 0)														
		0	1	2	3	4	5	6	7	8	9	10	11	12	13	14
Peanut oil	none	100	100	100	100	100	100	70	20	20	10	10	0	0	0	0
SMIP 28	0.3	100	100	100	100	100	100	90	10	10	10	10	0	0	0	0
	1	100	100	100	100	100	100	100	70	30	20	20	10	0	0	0
	3	100	100	100	100	100	100	100	100	100	100	90	80	80	80	80
	10	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100
	30	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100
	100	100	100	100	100	100	100	100	100	80	80	40	30	30	30	30
SMIP 29	0.3	100	100	100	100	100	100	100	90	70	50	50	50	50	50	50
	1	100	100	100	100	100	100	100	100	100	100	90	90	90	90	90
	3	100	100	100	100	100	100	100	100	90	80	80	70	70	70	70
	10	100	100	100	90	90	90	90	90	70	30	20	20	20	20	20
	30	100	100	100	100	100	100	100	100	30	10	10	0	0	0	0
	100	100	100	100	100	100	100	100	100	30	0	0	0	0	0	0

nr: not reported

EboZ: mouse-adapted strain derived from the Zaire strain of Ebola virus